NWBO was not even close to commercial manufacturing readiness in 2014. People should review their January 2014 expansion manifesto. Avii shows relevant FDA dialogue that would not likely permit approval based on INTERIM PFS (back in the day).
AF’s statement that DCVax-l Phase iii weakness or futility were the only possibilities (when only a safety analysis in 2014 was conducted) is illogical rhetoric. No efficacy analysis was conducted in 2014. The latter was confirmed by the DMC chairman.
News 
Market Data 
Discover 
AI
